دورية أكاديمية
EGFR activation limits the response of liver cancer to lenvatinib.
| العنوان: | EGFR activation limits the response of liver cancer to lenvatinib. |
|---|---|
| المؤلفون: | Jin H; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Shi Y; Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Lv Y; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Yuan S; The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China., Ramirez CFA; Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Lieftink C; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Wang L; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Wang S; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Wang C; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Dias MH; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Jochems F; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Yang Y; The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China., Bosma A; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Hijmans EM; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Groot MHP; Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Vegna S; Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Cui D; Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Zhou Y; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Ling J; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Wang H; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Guo Y; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Zheng X; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Isima N; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Wu H; Department of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, The Netherlands., Sun C; Division of Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Immune Regulation in Cancer Group, German Cancer Research Center, Heidelberg, Germany., Beijersbergen RL; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Akkari L; Division of Tumour Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Zhou W; The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China. ehphwp@126.com., Zhai B; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhaiboshi@sina.com.; Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhaiboshi@sina.com., Qin W; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. wxqin@sjtu.edu.cn., Bernards R; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. r.bernards@nki.nl. |
| المصدر: | Nature [Nature] 2021 Jul; Vol. 595 (7869), pp. 730-734. Date of Electronic Publication: 2021 Jul 21. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Basingstoke : Nature Publishing Group Original Publication: London, Macmillan Journals ltd. |
| مواضيع طبية MeSH: | Antineoplastic Agents/*pharmacology , Carcinoma, Hepatocellular/*metabolism , Liver Neoplasms/*metabolism , Phenylurea Compounds/*pharmacology , Quinolines/*pharmacology, Animals ; Carcinoma, Hepatocellular/drug therapy ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Female ; Gefitinib/pharmacology ; Humans ; Liver Neoplasms/drug therapy ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Receptors, Fibroblast Growth Factor ; Signal Transduction ; Xenograft Model Antitumor Assays |
| مستخلص: | Hepatocellular carcinoma (HCC)-the most common form of liver cancer-is an aggressive malignancy with few effective treatment options 1 . Lenvatinib is a small-molecule inhibitor of multiple receptor tyrosine kinases that is used for the treatment of patients with advanced HCC, but this drug has only limited clinical benefit 2 . Here, using a kinome-centred CRISPR-Cas9 genetic screen, we show that inhibition of epidermal growth factor receptor (EGFR) is synthetic lethal with lenvatinib in liver cancer. The combination of the EGFR inhibitor gefitinib and lenvatinib displays potent anti-proliferative effects in vitro in liver cancer cell lines that express EGFR and in vivo in xenografted liver cancer cell lines, immunocompetent mouse models and patient-derived HCC tumours in mice. Mechanistically, inhibition of fibroblast growth factor receptor (FGFR) by lenvatinib treatment leads to feedback activation of the EGFR-PAK2-ERK5 signalling axis, which is blocked by EGFR inhibition. Treatment of 12 patients with advanced HCC who were unresponsive to lenvatinib treatment with the combination of lenvatinib plus gefitinib (trial identifier NCT04642547) resulted in meaningful clinical responses. The combination therapy identified here may represent a promising strategy for the approximately 50% of patients with advanced HCC who have high levels of EGFR. (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.) |
| التعليقات: | Comment in: Nat Rev Drug Discov. 2021 Sep;20(9):668. (PMID: 34344998) Comment in: Nat Rev Gastroenterol Hepatol. 2021 Oct;18(10):675. (PMID: 34404918) Comment in: Signal Transduct Target Ther. 2021 Oct 4;6(1):359. (PMID: 34608130) Comment in: Hepatobiliary Surg Nutr. 2022 Feb;11(1):139-142. (PMID: 35284507) |
| References: | Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450–1462 (2019). (PMID: 10.1056/NEJMra1713263) Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163–1173 (2018). (PMID: 10.1016/S0140-6736(18)30207-1) Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021). (PMID: 10.3322/caac.21660) Zucman-Rossi, J., Villanueva, A., Nault, J.-C. & Llovet, J. M. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149, 1226–1239 (2015). (PMID: 10.1053/j.gastro.2015.05.061) Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008). (PMID: 10.1056/NEJMoa0708857) Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020). (PMID: 10.1056/NEJMoa1915745) Evers, B. et al. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat. Biotechnol. 34, 631–633 (2016). (PMID: 10.1038/nbt.3536) Zhu, A. X. et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 33, 559–566 (2015). (PMID: 10.1200/JCO.2013.53.7746) Matsuki, M. et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 7, 2641–2653 (2018). (PMID: 10.1002/cam4.1517) Wagle, M.-C. et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis. Oncol. 2, 7 (2018). (PMID: 10.1038/s41698-018-0051-4) Pirker, R. et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 13, 33–42 (2012). (PMID: 10.1016/S1470-2045(11)70318-7) Kimura, T. et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 109, 3993–4002 (2018). (PMID: 10.1111/cas.13806) Li, E., Lin, L., Chen, C. W. & Ou, D. L. Mouse models for immunotherapy in hepatocellular carcinoma. Cancers (Basel) 11, 1800 (2019). (PMID: 10.3390/cancers11111800) Keng, V. W. et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat. Biotechnol. 27, 264–274 (2009). (PMID: 10.1038/nbt.1526) He, H. et al. Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases. J. Biol. Chem. 276, 26741–26744 (2001). (PMID: 10.1074/jbc.C100229200) Lee, S.-W. et al. EGFR–Pak signaling selectively regulates glutamine deprivation-induced macropinocytosis. Dev. Cell 50, 381–392 (2019). (PMID: 10.1016/j.devcel.2019.05.043) Vaseva, A. V. et al. KRAS suppression-induced degradation of MYC is antagonized by a MEK5–ERK5 compensatory mechanism. Cancer Cell 34, 807–822 (2018). (PMID: 10.1016/j.ccell.2018.10.001) Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307–321 (2012). (PMID: 10.1016/j.cell.2012.02.053) Lito, P. et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668–682 (2012). (PMID: 10.1016/j.ccr.2012.10.009) Kosoff, R. E. et al. Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization. Blood 125, 2995–3005 (2015). (PMID: 10.1182/blood-2014-10-604504) Kobayashi, S. et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 66, 11389–11398 (2006). (PMID: 10.1158/0008-5472.CAN-06-2318) Philip, P. A. et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 23, 6657–6663 (2005). (PMID: 10.1200/JCO.2005.14.696) Chan, S. L. et al. New utility of an old marker: serial α-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J. Clin. Oncol. 27, 446–452 (2009). (PMID: 10.1200/JCO.2008.18.8151) Llovet, J. M. & Lencioni, R. mRECIST for HCC: performance and novel refinements. J. Hepatol. 72, 288–306 (2020). (PMID: 10.1016/j.jhep.2019.09.026) Ding, X. et al. Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas. Gastroenterology 157, 1630–1645 (2019). (PMID: 10.1053/j.gastro.2019.09.005) Cremolini, C. et al. Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann. Oncol. 26, 1188–1194 (2015). (PMID: 10.1093/annonc/mdv112) Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014). (PMID: 10.1186/s13059-014-0550-8) Jin, H. et al. Regulator of calcineurin 1 gene isoform 4, down-regulated in hepatocellular carcinoma, prevents proliferation, migration, and invasive activity of cancer cells and metastasis of orthotopic tumors by inhibiting nuclear translocation of NFAT1. Gastroenterology 153, 799–811 (2017). (PMID: 10.1053/j.gastro.2017.05.045) Mazières, J. et al. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. Lung Cancer 82, 231–237 (2013). (PMID: 10.1016/j.lungcan.2013.07.016) Sun, C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118–122 (2014). (PMID: 10.1038/nature13121) Wang, L. et al. High-throughput functional genetic and compound screens identify targets for senescence induction in cancer. Cell Rep. 21, 773–783 (2017). (PMID: 10.1016/j.celrep.2017.09.085) Schuhmacher, M. et al. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res. 29, 397–406 (2001). (PMID: 10.1093/nar/29.2.397) Wang, C. et al. Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature 574, 268–272 (2019). (PMID: 10.1038/s41586-019-1607-3) World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull. World Health Organ. 79, 373–374 (2001). (PMID: 2566407) |
| معلومات مُعتمدة: | International ERC_ European Research Council |
| سلسلة جزيئية: | ClinicalTrials.gov NCT04642547 |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Phenylurea Compounds) 0 (Quinolines) 0 (Receptors, Fibroblast Growth Factor) EC 2.7.10.1 (EGFR protein, human) EC 2.7.10.1 (ErbB Receptors) EE083865G2 (lenvatinib) S65743JHBS (Gefitinib) |
| تواريخ الأحداث: | Date Created: 20210722 Date Completed: 20220126 Latest Revision: 20230202 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1038/s41586-021-03741-7 |
| PMID: | 34290403 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1476-4687 |
|---|---|
| DOI: | 10.1038/s41586-021-03741-7 |